Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience
- PMID: 36098658
- PMCID: PMC9679265
- DOI: 10.2337/dc22-0860
Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience
Abstract
Objective: To determine glycemic and nonglycemic risk factors that contribute to the presence of diabetic retinopathy (DR) before and after the onset of type 2 diabetes (T2D).
Research design and methods: During the Diabetes Prevention Program (DPP) and DPP Outcome Study (DPPOS), we performed fundus photography over time in adults at high risk for developing T2D, including after they developed diabetes. Fundus photographs were graded using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system, with DR defined as typical lesions of DR (microaneurysms, exudates, hemorrhage, or worse) in either eye.
Results: By DPPOS year 16 (∼20 years after random assignment into DPP), 24% of 1,614 participants who had developed T2D and 14% of 885 who remained without diabetes had DR. In univariate analyses, using results from across the entire duration of follow-up, American Indian race was associated with less frequent DR compared with non-Hispanic White (NHW) race, and higher HbA1c, fasting and 2-h plasma glucose levels during an oral glucose tolerance test, weight, and history of hypertension, dyslipidemia, and smoking, but not treatment group assignment, were associated with more frequent DR. On multivariate analysis, American Indian race was associated with less DR compared with NHW (odds ratio [OR] 0.36, 95% CI 0.20-0.66), and average HbA1c was associated with more DR (OR 1.92, 95% CI 1.46-1.74 per SD [0.7%] increase in HbA1c).
Conclusions: DR may occur in adults with prediabetes and early in the course of T2D. HbA1c was an important risk factor for the development of DR across the entire glycemic range from prediabetes to T2D.
© 2022 by the American Diabetes Association.
Figures
References
-
- Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 - PubMed
-
- UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865 - PubMed
-
- Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK048412/DK/NIDDK NIH HHS/United States
- U01 DK048375/DK/NIDDK NIH HHS/United States
- U01 DK048434/DK/NIDDK NIH HHS/United States
- U01 DK048413/DK/NIDDK NIH HHS/United States
- M01 RR016587/RR/NCRR NIH HHS/United States
- U01 DK048339/DK/NIDDK NIH HHS/United States
- U01 DK048468/DK/NIDDK NIH HHS/United States
- U01 DK048387/DK/NIDDK NIH HHS/United States
- U01 DK048404/DK/NIDDK NIH HHS/United States
- P30 DK020595/DK/NIDDK NIH HHS/United States
- U01 DK048377/DK/NIDDK NIH HHS/United States
- U01 DK048407/DK/NIDDK NIH HHS/United States
- U01 DK048437/DK/NIDDK NIH HHS/United States
- U01 DK048406/DK/NIDDK NIH HHS/United States
- U01 DK048397/DK/NIDDK NIH HHS/United States
- U01 DK048381/DK/NIDDK NIH HHS/United States
- U01 DK048514/DK/NIDDK NIH HHS/United States
- U01 DK048485/DK/NIDDK NIH HHS/United States
- U01 DK048411/DK/NIDDK NIH HHS/United States
- U01 DK048443/DK/NIDDK NIH HHS/United States
- U01 DK048380/DK/NIDDK NIH HHS/United States
- U01 DK048400/DK/NIDDK NIH HHS/United States
- U01 DK048489/DK/NIDDK NIH HHS/United States
- U01 DK048349/DK/NIDDK NIH HHS/United States
